Aberrant lipid metabolism as a therapeutic target in liver cancer

Evans D. Pope, Erinmarie O. Kimbrough, Lalitha Padmanabha Vemireddy, Phani Keerthi Surapaneni, John A III Copland, Kabir Mody

Research output: Contribution to journalArticle

Abstract

Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.

Original languageEnglish (US)
Pages (from-to)473-483
Number of pages11
JournalExpert opinion on therapeutic targets
Volume23
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Liver Neoplasms
Lipid Metabolism
Liver
Hepatocellular Carcinoma
Fatty Acids
Monoacylglycerol Lipases
ATP Citrate (pro-S)-Lyase
Cells
Neoplasms
Acetyl-CoA Carboxylase
Fatty Acid Synthases
AMP-Activated Protein Kinases
Therapeutics
Tumors
Expert Testimony
Metabolic Networks and Pathways
Lipids
PubMed
Acids
Cell Survival

Keywords

  • Fatty acid
  • hepatocellular carcinoma
  • lipid metabolism
  • lipids
  • liver cancer
  • SCD1
  • stearoyl co-A desaturase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Aberrant lipid metabolism as a therapeutic target in liver cancer. / Pope, Evans D.; Kimbrough, Erinmarie O.; Vemireddy, Lalitha Padmanabha; Surapaneni, Phani Keerthi; Copland, John A III; Mody, Kabir.

In: Expert opinion on therapeutic targets, Vol. 23, No. 6, 03.06.2019, p. 473-483.

Research output: Contribution to journalArticle

Pope, Evans D. ; Kimbrough, Erinmarie O. ; Vemireddy, Lalitha Padmanabha ; Surapaneni, Phani Keerthi ; Copland, John A III ; Mody, Kabir. / Aberrant lipid metabolism as a therapeutic target in liver cancer. In: Expert opinion on therapeutic targets. 2019 ; Vol. 23, No. 6. pp. 473-483.
@article{e512c7f6b18f4269985b19a46b7dd0b9,
title = "Aberrant lipid metabolism as a therapeutic target in liver cancer",
abstract = "Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.",
keywords = "Fatty acid, hepatocellular carcinoma, lipid metabolism, lipids, liver cancer, SCD1, stearoyl co-A desaturase",
author = "Pope, {Evans D.} and Kimbrough, {Erinmarie O.} and Vemireddy, {Lalitha Padmanabha} and Surapaneni, {Phani Keerthi} and Copland, {John A III} and Kabir Mody",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/14728222.2019.1615883",
language = "English (US)",
volume = "23",
pages = "473--483",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Aberrant lipid metabolism as a therapeutic target in liver cancer

AU - Pope, Evans D.

AU - Kimbrough, Erinmarie O.

AU - Vemireddy, Lalitha Padmanabha

AU - Surapaneni, Phani Keerthi

AU - Copland, John A III

AU - Mody, Kabir

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.

AB - Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.

KW - Fatty acid

KW - hepatocellular carcinoma

KW - lipid metabolism

KW - lipids

KW - liver cancer

KW - SCD1

KW - stearoyl co-A desaturase

UR - http://www.scopus.com/inward/record.url?scp=85065708943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065708943&partnerID=8YFLogxK

U2 - 10.1080/14728222.2019.1615883

DO - 10.1080/14728222.2019.1615883

M3 - Article

VL - 23

SP - 473

EP - 483

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 6

ER -